Morris Kelley, MD
Cardiovascular Disease · North Little Rock, ARNPI 1104939636
Payments from drug & device makers
Across 458 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AstraZeneca$1K
- Johnson & Johnson$696
- Boston Scientific$670
- Abiomed$655
- Amgen$574
- plus $4K from 29 others
What the payments were for
- Travel & lodging$3123%
- Food & beverage$9,27796%
- Education$1131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 129 | $1,576 |
| AstraZeneca | 35 | $1,042 |
| Johnson & Johnson | 44 | $696 |
| Boston Scientific | 12 | $670 |
| Abiomed | 8 | $655 |
| Amgen | 31 | $574 |
| Boehringer Ingelheim | 27 | $534 |
| Pfizer | 33 | $511 |
| Irhythm Technologies, Inc. | 11 | $458 |
| Shockwave Medical, Inc | 3 | $448 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $341 |
| Sanofi-aventis U.S. LLC | 17 | $311 |
| Esperion Therapeutics, Inc. | 6 | $277 |
| Alnylam Pharmaceuticals Inc. | 10 | $254 |
| Merck | 11 | $193 |
| Amarin Pharma, Inc. | 11 | $170 |
| Astellas Pharma US Inc | 3 | $142 |
| E.r. Squibb & Sons, L.L.C. | 7 | $111 |
| Baxter Healthcare | 5 | $91 |
| Actelion Pharmaceuticals US, Inc. | 4 | $73 |
| Medtronic(2 entities) | 4 | $68 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $65 |
| Bayer | 4 | $64 |
| Abbott | 3 | $63 |
| Cardiovascular Systems Inc. | 2 | $50 |
| Inari Medical, Inc. | 1 | $40 |
| Lundbeck LLC | 2 | $40 |
| Gilead | 3 | $38 |
| Philips North America LLC | 2 | $34 |
| Innovation Technologies Inc | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,702 in reported general payments places this provider in the 70th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $223,877 |
| EntrestoSacubitril/Valsartan | 73 | $76,299 |
| FarxigaDapagliflozin Propanediol | 89 | $75,861 |
| JardianceEmpagliflozin | 17 | $15,728 |
| XareltoRivaroxaban | 17 | $13,321 |
| Repatha SureclickEvolocumab | 17 | $9,081 |
| BrilintaTicagrelor | 13 | $7,123 |
| Triamterene | 12 | $3,852 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 134 | $3,629 |
| Metoprolol Succinate | 282 | $3,375 |
| Ranolazine ErRanolazine | 22 | $3,285 |
| Diltiazem 24hr ErDiltiazem Hcl | 119 | $2,941 |
| Diltiazem 12hr ErDiltiazem Hcl | 16 | $2,614 |
| Isosorbide Dinitrate | 54 | $2,530 |
| Ezetimibe | 137 | $2,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $511 | $223,877233 claims |
| AstraZenecaFarxiga, Brilinta | $1,042 | $82,984102 claims |
| NovartisEntresto | $1,576 | $76,29973 claims |
| Boehringer IngelheimJardiance | $534 | $15,72817 claims |
| Johnson & JohnsonXarelto | $696 | $13,32117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in North Little Rock
- Thomas ConleyNorth Little Rock$12K
- Mark St PierreNorth Little Rock$10K
- Marvin AshfordNorth Little Rock$7K
- Jay GeoghaganNorth Little Rock$6K
- Charles CaldwellNorth Little Rock$5K
- Ian CawichLittle Rock$1.1M
- Christian Assad KottnerLittle Rock$670K
- Barry UretskyLittle Rock$609K
- Maximiliano ArroyoJonesboro$553K
- William RollefsonLittle Rock$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.